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Purpose: Variants in the DNA mismatch repair (MMR) gene
MSH6, identified in individuals suspected of Lynch syndrome, are
difficult to classify owing to the low cancer penetrance of defects in
that gene. This not only obfuscates personalized health care but also
the development of a rapid and reliable classification procedure that
does not require clinical data.
Methods: The complete in vitro MMR activity (CIMRA) assay
was calibrated against clinically classified MSH6 variants and,
employing Bayes’ rule, integrated with computational predictions of
pathogenicity. To enable the validation of this two-component
classification procedure we have employed a genetic screen to
generate a large set of inactivating Msh6 variants, as proxies for
pathogenic variants.
Results: The genetic screen-derived variants established that the
two-component classification procedure displays high sensitivities
and specificities. Moreover, these inactivating variants enabled the
direct reclassification of human variants of uncertain significance
(VUS) as (likely) pathogenic.
Conclusion: The two-component classification procedure and the
genetic screens provide complementary approaches to rapidly and
cost-effectively classify the large majority of human MSH6 variants.
The approach followed here provides a template for the classifica-
tion of variants in other disease-predisposing genes, facilitating the
translation of personalized genomics into personalized health care.
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INTRODUCTION
Lynch syndrome (LS, OMIM 120435) is an autosomal
dominant cancer predisposition, caused by a germline defect
in a single allele of one of the mismatch repair (MMR) genes
MSH2, MSH6, MLH1, or PMS2.1–3 Sporadic somatic loss of
the wild-type allele results in cellular MMR deficiency. The
mutator phenotype that results from the inability to correct
DNA replication errors lies at the origin of LS-associated
colorectal and endometrial cancers.1,2
Missense variants comprise a significant fraction of the
genetic variants identified in the MMR genes, particularly in
MSH6.3 In case such a variant cannot be classified as (likely)
pathogenic or (likely) non-pathogenic, personalized health
care for affected families cannot be implemented.2,4
The Variant Interpretation Committee (VIC) of the
International Society for Gastrointestinal Hereditary Tumors
(InSiGHT; https://www.insight-group.org) has devised the use
of qualitative or quantitative integration of evidence to classify
variants in the MMR genes, employing standards set by the
International Agency for Research on Cancer (IARC).5
Unfortunately, classification of MSH6 variants has proven
particularly difficult owing to the relatively low penetrance of
cancer in LS patients with a proven MSH6 defect, which
complicates the use of cosegregation as a diagnostic tool.5–7
For this reason, the VIC has been able to classify only a few
MSH6 variants as pathogenic (IARC class 5, probability
of pathogenicity >0.99), likely pathogenic (IARC class 4,
probability of pathogenicity > 0.95), likely not pathogenic
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(IARC class 2, probability of pathogenicity < 0.05), or not
pathogenic (IARC class 1, probability of pathogenicity
< 0.001), with associated clinical recommendations.4,6 There-
fore, the large majority of variants in MSH6 remain variants
of uncertain significance (VUS; IARC class 3, probability of
pathogenicity between 0.05 and 0.95).4–6
Functional assays may strongly contribute to improved
classification of MMR gene variants.4,8–11 We have developed
the complete in vitro MMR activity (CIMRA) assay to quantify
the functional activity of variants in MMR genes.12–15 The
assay can be performed in a few days using common laboratory
equipment and only requires information on the variant
(Fig. 1a). Such a functional assay–based classification proce-
dure can only be transferred to the clinic following thorough
calibration and validation. Calibration involves the regression
of the assay output against the clinical odds in favor of
pathogenicity (odds path) of a set of variants that have
previously been securely classified by using clinical criteria
only. The resulting regression formula converts the CIMRA
assay result into odds path for the CIMRA assay, the variable
that can be combined, using Bayes’ rule, with other calculated
probabilities of pathogenicity, such as computational analysis,
into a posterior probability (Posterior-P) of pathogenicity. The
subsequent determination of the sensitivities and specificities of
such a two-component classification procedure requires an
unrelated validation set comprised of independently classified
variants. We have recently followed a similar approach to
develop a procedure to classify variants in MSH2 and MLH1.15
Unfortunately, because insufficient classified MSH6 variants
are available, validation of a functional assay–based predictive
procedure for variants in MSH6 has been extremely
challenging.
Here, we have used the available clinically classified MSH6
variants to calibrate the CIMRA assay output and allow its
Bayesian integration with previously calibrated and validated
computational analysis into a two-component classification
procedure. Then, we addressed the shortage of classified
variants for validation purposes by generating a large number
of in vivo inactivating Msh6 variants in a cell-based genetic
screen. We have extensively characterized these variants,
using cellular and biochemical analyses, to confirm their
suitability as a proxy for pathogenic human variants. This has
enabled the validation of the two-component classification
procedure. Moreover, our finding that many inactivating
variants identified in the genetic screen match human MSH6
VUS listed in variant databases supports their classification as
pathogenic.
MATERIALS AND METHODS
Selection of classified missense substitutions for CIMRA
assay calibration
In July 2017 we reviewed the InSiGHT variant database
(http://insight-group.org/variants/database) for MSH6 var-
iants that, by using clinical criteria alone, were classified as
IARC class 4/5 or as class 1/2.5 We excluded those variants
that had been used for calibration of the computational prior
probability of pathogenicity (Prior-P).16 This resulted in a set
of 24 variants. Since this number appeared insufficient for a
robust calibration, we added 7 variants that have been
classified as class 3 (VUS), although with observational data
≥3-fold evidence in favor of pathogenicity or ≥3-fold evidence
against pathogenicity (Table S1).
Complete CIMRA assays
CIMRA assays of MSH6 variants were carried out as
described,15,17 with a change of the use of nuclear extracts.
To enable the production of highly active nuclear extracts,18
we generated MSH2 and MSH6 double-deficient HeLa cells.
Briefly, cells were made MSH2-deficient with a CRISPR/Cas9
construct; these cells were selected using 6-thioguanine
(20 µM). In these cells we also disrupted MSH6, using
CRISPR/Cas9; MSH6-deficient clones were identified by
polymerase chain reaction (PCR). Loss of both genes was
verified by PCR and western blotting using Msh6 antibody
ab14204 (Abcam).19 Detailed protocols and primer sequences
are available upon request.
Regression for CIMRA assay calibration
For CIMRA assay calibration, InSiGHT observational odds in
favor of pathogenicity in the form of Log10(Odds Path) was
treated as the dependent variable.15 The normalized CIMRA
assay values of the same variants were treated as the
independent variable. We then performed linear regression
on Log10(Odds Path) versus CIMRA assay values, whereby
the use of Log(Odds) as the dependent variable constrains the
resulting regression equations to produce probabilities
between 0.00 and 1.00.
Computational analyses and Bayesian integration
Computational analyses predicting the probability of patho-
genicity for each variant were performed using the calibrated
and validated programs MAPP and PolyPhen-2, as previously
reported.16 We used the resulting values as the Prior-P, setting
upper and lower caps for Prior-P values at 0.10 and 0.90, to
avoid classification as class 1/2 or class 4/5, based on
computational prediction alone.16 The Prior-P is amenable
to quantitative integration with the calibrated CIMRA assay
results, to obtain a Posterior-P.5,20 Such a two-component
classification procedure has previously been performed to
integrate computational results with clinical parameters (such
as segregation and tumor pathology), based on odds path.21,22
Generation of a set of independently classified variants for
validation
To compile an independent validation set we reviewed the
content of both the InSiGHT and ClinVar variant databases
(https://www.ncbi.nlm.nih.gov/clinvar) for MSH6 variants
that had met ClinVar or InSiGHT classification as (likely)
benign/not pathogenic or (likely) pathogenic. We excluded
variants that were used for calibration of the CIMRA assay or
of the Prior-P,16 resulting in 18 remaining (likely) benign
variants (Table S3).
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No new, independently classified, class 4/5 variants were
obtained from the databases. To obtain such variants we
performed a genetic screen, essentially as described for
Msh2.19 Briefly, we used the mutagen N-ethyl-N-nitrosourea
(ENU; Sigma-Aldrich, St. Louis, MO) to introduce random
substitution variants in Msh6-heterozygous mouse embryonic
stem (mES) cells.23 Prior to use these cells were authenticated
by PCR and mycoplasm testing. Since these cells are diploid
for all other MMR genes than Msh6, MMR-deficient clones
that were selected using 6-thioguanine (6-TG, Sigma-Aldrich)
were expected to have lost the single Msh6 allele, rather than
both copies of one of the other three MMR genes.24 Surviving
clones were screened against inadvertent loss of heterozygos-
ity of the Msh6 wild-type allele, rather than an ENU-induced
substitution variant, by allele-specific PCR. We then screened
against clones that did not express full-length Msh6
complementary DNA (cDNA), e.g., with nonsense or splice
variants, by western blotting.23 To identify the ENU-induced
substitutions that had inactivated the single wild-type Msh6
allele by a single missense variant, we sequenced Msh6 cDNA
from the remaining clones. All primer sequences and PCR
protocols are available upon request.
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Fig. 1 Outline, calibration and validation of the complete in vitro mismatch repair activity (CIMRA) assay. (a) Outline of the CIMRA assay.
(b) Relative repair efficiencies for MSH6 missense variants from the InSiGHT database, classified based on clinical criteria alone. Variants are ranked according
to their mean CIMRA assay activity. The p.G1139S variant is included in every experiment as a (technical) repair-deficient control. Variants are colored
according to their International Agency for Research on Cancer (IARC) classification (see figure for legend). Bars represent mean ± S.E.M. of >3 experiments.
(c) Regressions of the CIMRA assay training values against odds in favor of pathogenicity. The y-axes of these graphs display probability of pathogenicity
rather than Log(odds in favor of pathogenicity) to emphasize sigmoid calibration bounded at probabilities of 1.00 and 0.00. (d) Relative repair efficiencies for
InSiGHT/ClinVar database-derived (likely) benign MSH6 missense variants (blue bars) as determined in the CIMRA assay. Variants are ranked according to
their mean CIMRA assay activity. Bars represent mean ± S.E.M. of >3 experiments. MMR mismatch repair, PCR polymerase chain reaction, WT wild type.
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Assays to provide mechanistic insights in inactivating Msh6
substitutions obtained by a genetic screen
Microsatellite instability (MSI) was analyzed after PCR
amplification of mononucleotide microsatellite mBAT-37
on ~50 subclones of variants each cell line tested.25
Fragment lengths were analyzed using GeneMarker soft-
ware (Softgenetics).
Methylation tolerance was determined as follows: cells were
treated for 1 hour with N-methyl-N’-nitro-N-nitrosoguani-
dine (MNNG; Sigma-Aldrich) dissolved in dimethyl sulfoxide
(DMSO), in increasing concentrations. O6-benzylguanine (40
µM; Sigma-Aldrich), an inhibitor of the repair protein
methyltransferase, was added during treatment. After 3 days,
IC50s were derived after counting of surviving cells.
Electrophoretic mobility shift assays were carried out
using extracts from the variant cell lines, essentially as
described.19,26 Oligonucleotides 5′-AGCTGCCAAGCACCA
GTGTCAGCGTCCTAT-3′ and 5′-AGCTGCCAGGCACCA
GTGTCAGCG TCCTAT-3′ were labeled at the 5′ end using
γ-32P adenosine triphosphate (ATP) and polynucleotide
kinase, and were both annealed to oligonucleotide 5′-ATA
GGACGCTGACACTGGTGCTTGGCAGCT-3′ to generate a
matched and a G·T mismatched (underlined) probe, respec-
tively. Then, 170 fmol double-stranded oligonucleotide was
incubated with 20 μg extract in DNA binding buffer (12%
[vol/vol] glycerol, 20 mM Hepes/KOH pH 7.9, 100 mM NaCl,
1 mM DTT, and 0.1 mM EDTA, 0.05 μg/μL Poly[dIdC]) and
425 fmol unlabeled, matched oligonucleotide) for 20 minutes
at 37°C in a total volume of 20 μL. For challenge experiments,
ATP (final concentration 0.5 mM) was added 10 minutes after
addition of the DNA probe. The reaction mixture was
subjected to electrophoresis in a 4% polyacrylamide:bisacry-
lamide (29:1) gel in 0.5× TBE buffer containing 5% glycerol.
Gels were dried, signals were visualized using a Cyclone Plus
phosphor imager (PerkinElmer), and images were analyzed
using OptiQuant software. All mismatch binding assay results
were confirmed on independent cell extracts.
Sensitivity and specificity at the classification thresholds
Probabilities of pathogenicity were calculated following
Bayesian integration of the computational Prior-P with the
CIMRA assay values. Variants analyzed as having a Posterior-
P of pathogenicity >0.95 were classified as class 4/5 whereas
variants with a Posterior-P of pathogenicity <0.05 were
classified as class 1/2. All other variants were classified as class
3 (VUS).
Sensitivities and specificities of the two-component
(computational analysis and CIMRA assay) classification
procedure were investigated using an independent valida-
tion set of variants that consisted of inactivating variants,
generated in the genetic screen, and of benign variants
derived from the ClinVar and InSiGHT databases. Sensi-
tivity of the two-component procedure for class 4/5 variants
was estimated as (# true positives)/(# inactivating variants).
Specificity was estimated as (# true negatives)/(# [likely]
benign variants).
Sensitivity of the two-component procedure for class 1/2
variants, derived from the ClinVar and InSiGHT databases,
was estimated as (# true positives)/(# [likely] benign variants).
Specificity was estimated as (# true negatives)/(# inactivating
variants).
Multilaboratory assessment of CIMRA assay reproducibility
Variants used for in the multilaboratory assessment of
CIMRA assay reproducibility were selected from the variants
included in the calibration effort based on differential
activities in the assay and differential positions within MSH6.
CIMRA assays were performed according to a protocol
provided by Leiden University Medical Center (LUMC).
Participating labs received technical support by email, when
needed. Reagents (e.g., buffer and nuclear extract-containing
CIMRA assay mix, substrate plasmid, etc.) were prepared at
the LUMC and distributed to participating labs by mail.
All commercially available components (e.g., TNT Quick
Coupled Translation kit, Pfx Platinum polymerase, etc.) were
purchased by the participating laboratories.
RESULTS
CIMRA assay calibration for quantitative data integration
To enable the integration of CIMRA assay results with other
quantitative data, such as sequence analysis–based computa-
tional algorithms,5,20 we determined MMR activity of a
calibration set consisting of 24 MSH6 missense variants
selected from the InSiGHT database that had previously been
securely classified using clinical criteria only (Fig. 1b and
Table S1). CIMRA assay results were largely concordant with
their previously assigned class (Fig. 1b and Table S1).
Notably, all pathogenic variants displayed an activity in the
CIMRA assay that was <25% of the wild-type control. To
increase the power of the subsequent regression we included 7
VUS that had observational data providing ≥3-fold evidence
in favor of, or against, pathogenicity (Fig. 1b and Table S1).
We then performed linear regression of the CIMRA assay
results of these 31 variants against log-transformed clinical
odds in favor of pathogenicity, to derive a regression equation
[Log10(Odds Path)=−0.0303508 (% activity)+ 1.845465]
(Fig. 1c). This equation enables conversion of CIMRA assay
activities into odds in favor of pathogenicity—the variable
that can be combined with other quantitative variables, using
Bayes’ rule, to calculate a Posterior-P.4–6,15,16,20,27
We argued that, while loss of functional activity presumably
predicts pathogenicity of a variant, the in vitro nature of the
CIMRA assay might lead to false-negative results, e.g., when
the variant would destabilize the protein in vivo. We therefore
used Bayes’ rule to quantitatively integrate the CIMRA
assay–based odds with a Prior-P of pathogenicity derived
from sequence alignment-based algorithms that have been
previously calibrated.16 This yielded a Posterior-P of patho-
genicity, required for classification. All 11 variants from the
calibration set that had been clinically classified as class 4/5 by
InSiGHT were classified as pathogenic (class 5) by the
two-component classification. Conversely, of 13 variants
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previously classified as class 1/2, the two-component
classification classified 9 as (likely) not pathogenic (class 1/
2), while classifying 4 as VUS (class 3). Importantly, no
variants were misclassified (Table S1). The seven VUS were
included for calibration purposes only and therefore have not
been further classified.
Following recent guidelines established by the American
College of Medical Genetics and Genomics and the Associa-
tion for Molecular Pathology (ACMG/AMP), functional
assays are considered to provide “strong” evidence in favor
of or against pathogenicity (PS3/BS3).4 After CIMRA assay
calibration and quantitative modeling of the ACMG/AMP
criteria, the calculated CIMRA values can fall into any of six
strength of evidence categories in favor of or against
pathogenicity, as defined by ACMG/AMP (Table S2).4,27
A genetic screen for the identification of inactivating Msh6
missense variants
Validation of the two-component procedure should be
performed on an independent set of variants, securely
classified in the absence of functional or computational
data.28 We were able to extract 18 additional MSH6 class 1/2
variants from the InSiGHT and ClinVar databases that were
not present in the calibration set. In agreement with their
classification, 17/18 variants showed activities greater than
60% of wild type in the CIMRA assay (Fig. 1d). Bayesian
integration of the calibrated CIMRA assay results with the
Prior-P corroborated the clinical classification of 14 variants
as class 1/2, while four variants could not be classified using
the two-component approach (Table S3). Thus, the two-
component classification has a high sensitivity for class 1/2
variants.
Unfortunately, all MSH6 variants that, based on clinical
data, were classified as class 4/5 in InSiGHT/ClinVar had
already been employed in the calibration set and could
therefore not be used for validation of the two-component
classification (Fig. 1b). To still obtain in vivo inactivating
MSH6 variants for this aim we employed a genetic screen in
mouse embryonic stem cells (Fig. 2a), essentially as previously
described for Msh2.19 This procedure resulted in the retrieval
of 43 variant cell lines, each containing a random inactivating
amino acid substitution in Msh6. In these 43 cell lines, 38
residues were affected; at 5 of these residues two different
substitutions were identified, in different clones (Fig. 2b and
Table S4). Of the 43 substitutions, 41 involved an amino acid
that is conserved between mice and humans (Fig. S1 and
Table S4).
Genetic screens enable the identification of pathogenic
human MSH6 variants
We argued that our genetic screen, in addition to allowing the
validation of our two-component classification procedure,
might yield inactivating Msh6 variants that coincide with
previously identified, human MSH6 variants. This would
directly support the pathogenicity of such variants. Indeed, 13
inactivating variants identified in our genetic screen were also
found in the InSiGHT and ClinVar databases (Table S4).
These included two alleles that had been classified by the
InSiGHT VIC as class 4/5 and that were also used by us for
the calibration of the CIMRA assay (p.L449P, p.G686D;
Fig. 1b), as well as an allele we use as a “dead” control for the
assay (p.G1139S; Fig. 1b, d).12,17 Importantly, none of the 41
inactivating alleles identified in the genetic screen had been
classified by InSiGHT or ClinVar as class 1/2.
We wanted to further substantiate loss of in vivo MMR
activity specifically for the eight genetic screen-derived cell
lines of which the inactivating Msh6 variants matched
variants that are listed in the InSiGHT database (Table S4).
To this aim we first investigated microsatellite instability
(MSI), a hallmark of MMR-deficient cancers.29 Indeed, all
eight variant cell lines displayed MSI (Fig. 2c). In addition to a
spontaneous mutator phenotype, MMR deficiency causes
tolerance of methylating agents.30 As expected, all eight lines
displayed strong tolerance of the methylating drug MNNG
(Fig. 2d).
Inactivation of Msh6 function can be caused by different
molecular defects
To pinpoint the molecular defects in Msh6 protein function of
the variants identified in the genetic screen, and to further
validate these as a proxy for pathogenic MSH6 variants, we
performed biochemical analyses. MMR is initiated by binding
of the MSH2/MSH6 heterodimer to a mismatched nucleotide
pair.31–33 This induces ATP binding by both proteins,
provoking a conformational change that converts the
heterodimer into a clamp that slides on the DNA and binds
MLH1/PMS2.34 We argued that the 43 inactivating variants
from the genetic screen might either display a defect in any of
these activities of Msh2/Msh6, or destabilize the Msh2/Msh6
heterodimer.
Western blotting of all inactivating Msh6-variant cell lines
revealed that levels of the inactive Msh2/Msh6 proteins varied
between the 43 different cell lines, supporting destabilization
of some mutant proteins (Fig. 3a and Table S4). We then
tested the ability of all mutated Msh2/Msh6 proteins to bind
to mismatched oligonucleotides, employing electrophoretic
mobility shift assays with extracts from the corresponding
variant cell lines. The majority of the Msh6 variants displayed
either partial or complete loss of mismatch binding, in many
cases coinciding with reduced protein levels (Fig. 3a, b,
Table S4).
Finally, we tested ATP-induced sliding clamp formation of
those Msh2/Msh6 variants that had retained significant levels
of mismatch binding (Fig. 3b and Table S4). In contrast to
Msh2/Msh6-proficient cells, the addition of 0.5 mM ATP
failed to induce release in extracts from cells expressing Msh6
variants p.N1134K, p.M1135K, p.G1137D, p.G1137S, and p.
T1217I, explaining their defect in MMR (Fig. 3c, d, Table S4).
Thus, these variants display a specific defect in sliding clamp
formation.
In conclusion, using these specific biochemical assays, we
have obtained insights into the molecular cause of MMR
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deficiency for 38 of the 43 variant alleles but were unable to
do so for 5 substitutions (p.Q484K, p.Q484R, p.D1211E, p.
D1211G, and p.H1246R). The observation that two of these
amino acids each show two independent substitutions in
different MMR-deficient cell lines suggests that both amino
acids nevertheless are crucial for Msh6 function. We therefore
infer that these variants may be defective in other character-
istics of Msh2/Msh6.
The thorough biochemical characterization of the 43
inactivating variants produced in the genetic screen has
(1) confirmed their causality for MMR deficiency, (2) enabled
to pinpoint different biochemical defects as the cause of MMR
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Fig. 2 A genetic screen for inactivating missense variants in Msh6. (a) Pipeline to generate mouse embryonic stem (mES) cell lines that carry
inactivating Msh6 missense variants. I. A mES cell line, heterozygous for Msh6 (Msh6+/−), is subjected to mutagenic treatment with ENU. II. Cells that have
acquired 6-TG tolerance, by loss of heterozygosity at Msh6 (Msh6+/−), owing to an ENU-induced inactivating variant at a critical residue in the monoallelic
Msh6 gene (Msh6M/−), or by an inactivating variant at the monoallelic Hprt gene (Hprt-) are selected using two brief 6-TG selections. III. The (unwanted)
Hprt-deficient clones are eliminated by culture in HAT-supplemented medium. IV. Inadvertent clones that have lost the wild-type Msh6 allele by loss of
heterozygosity (LOH) (rather than by a missense substitution) are excluded by using an allele-specific polymerase chain reaction (PCR). V. The inactivating
substitution in the remaining clones is identified by sequence analysis. A “reverse diagnosis catalog” is compiled that lists inactivating substitutions at Msh6
as a proxy for pathogenic human variants (Fig. 4). (b) Representation of all inactivating missense substitutions in Msh6, identified in this screen. The top and
bottom panels show alignments of the mismatch binding and ATPase domains of human and mouse Msh6, highlighting residues that were mutated in the
genetic screen (orange boxes). Phe-X-Glu: mismatch-contacting loop. The middle panel displays all other inactivating Msh6 substitutions. Numbers reflect
amino acid numbering of mouse Msh6. (c) Microsatellite instability (MSI) analysis. The size of each sphere is proportional to the relative number of subclones
with the indicated mBAT-37 PCR fragment length. All mutants from the validation panel display MSI (p < 0.05 compared with the Msh6+/− line).
(d) Tolerance of Msh6 mutant mES cell lines to the methylating drug N-methyl-N′-nitro-N-nitrosoguanidine. Bars represent mean ± S.E.M. *p < 0.05,
**p < 0.01, ***p < 0.001 (one-tailed Student’s t test) compared with the parental Msh6+/− line.
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Fig. 3 Mechanism of mismatch repair (MMR) deficiency of Msh6 alleles identified in the genetic screen. (a) Western blot analysis of total lysates
from (Msh6-variant) ES cells. Pcna serves as a loading control. In addition to Msh6 we also probed for Msh2. Since Msh2 stability depends on Msh6, Msh2
proteins levels are a surrogate marker for Msh6 protein stability. (b) Binding of control and Msh6-variant proteins to a G·T mismatch within a double-
stranded oligonucleotide probe in an electrophoretic mobility shift assay. Bars represent mean ± S.E.M. of >3 experiments. (c) Adenosine triphosphate (ATP)-
induced mismatch release of Msh6-variant proteins in an electrophoretic mobility shift assay. ATP (0.5 mM) was added after allowing proteins to bind to the
probe. Bars represent mean ± S.E.M. For the purpose of clarity, all (-) ATP reactions are normalized to 1 and all (+) ATP reactions are normalized to their
respective (-) ATP reactions. Bars represent mean ± S.E.M. of >3 experiments. (d) Msh6-mutant proteins deficient for ATP-induced release (Fig. 3c) were
challenged with higher amounts of ATP in an electrophoretic mobility shift assay. ATP, in various concentrations, was added after allowing proteins to bind
to the probe. Bars represent mean ± S.E.M. For the purpose of clarity, all (-) ATP reactions are normalized to 1 and all (+) ATP reactions are normalized to
their respective (-) ATP reactions. Bars represent mean ± S.E.M. of >3 experiments. (e) Relative repair efficiencies, as determined in the complete in vitro
MMR activity (CIMRA) assay, for human MSH6 missense variants, corresponding to inactivating murine variants identified in the genetic screen. Variants are
ranked according to their mean CIMRA assay activity. Bars represent mean ± S.E.M. of >3 experiments/variant. The human, not the mouse, numbering of
the variants is shown. The numbers at the bottom of the figure indicate the International Agency for Research on Cancer (IARC) class for every variant
resulting from our calibrated two-component classification (Table S5).
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deficiency of these (and, by inference, also LS-associated)
variants, (3) demonstrated that the screen has provided an
independent tool to directly assign pathogenicity to human
MSH6 VUS that carry the identical substitution, and (4)
demonstrated that the genetic screen-derived pathogenic
variants serve as bona fide proxies for pathogenic human
variants, warranting their suitability for validation of the two-
component classification.
Validation of the two-component classification procedure
To validate the two-component classification, we used human
analogs of (mouse) inactivating variants, identified in the
genetic screen. From these variants we omitted Msh6 p.L872P
and p.L1154R, as the mutated leucines are not conserved
between mouse and human (Fig. S1, Table S4); p.L449P and
p.G686D, which were already used for the calibration; and
p.G1139S, which we routinely use as a “dead” control in the
CIMRA assay (Fig. 1b, c). For 32 of the remaining 38 (84%)
variants, CIMRA assay values were below 25% of wild-type
activity (Fig. 3e) while four variants displayed 25–50% and
two displayed >50% activity (Fig. 3e). Feeding these in vitro
activities into our regression equation, followed by integration
with the computational analysis–based Prior-P, resulted in the
two-component classification of 35 of the 38 variants as class
4/5, whereas only 3 remained class 3. Importantly, none were
falsely classified as class 1/2 (Table S5).
Calculating the sensitivities and specificities of the two-
component classification procedure revealed that the sensi-
tivity of classification to class 4/5 was 0.92 with a specificity of
1.00. The sensitivity of classification to class 1/2 was 0.78 with
a specificity of 1.00.
Interlab CIMRA assay comparison
To independently investigate the reproducibility of the
CIMRA assay, which is essential for its use as a diagnostic
tool, MMR activity of ten MSH6 variants from the calibration
set was determined in independent laboratories in Australia,
the United States, and the Netherlands. Assay results
appeared highly reproducible (Fig. 4).
DISCUSSION
The integration of multiple data sources to classify a variant
has been widely endorsed by the variant classification
community.4,5,8 By quantitatively combining results from
computational analysis with those from the calibrated CIMRA
we have developed, calibrated, and validated a two-component
classification procedure.
To enable validation, we have used a genetic screen
to generate an independent set of inactivating MSH6
variants. We have carefully validated the use of these
variants as proxies for human pathogenic variants. We
identified the biochemical mechanisms of MMR deficiency
for nearly all, and found that 13 of the 43 inactivating
substitutions identified in the genetic screen matched
previously identified human MSH6 variants. Of these 13
variants, 2 had been assigned class 4/5, by using clinical
criteria, whereas the others had remained unclassified.
Thus, our small-scale genetic screen already enabled to
assign pathogenicity to 11 human VUS demonstrating that,
in addition to the two-component classification, genetic
screens can be used as an independent tool to classify VUS.
Even so, the genetic screen remains a surrogate for
pathogenic human variants and a (small) possibility
remains that not all of these screen-detected variants reflect
true pathogenic human alleles. The sensitivities and
specificities of our two-component procedure could there-
fore be (slightly) upwardly biased.
Independently testing the two-component classification
on human counterparts of these “pathogenic” murine
variants and on 18 class 1/2 human variants revealed that
the two-component procedure classifies 88% of all MSH6
variants with very high sensitivities and specificities for both
class 4/5 and class 1/2 variants. Importantly, no variant was
misclassified (Tables S1, S3, S4). Combining results from
our recent two-component classification procedure for
variants in MLH1 and MSH215 with those for variants in
MSH6 reveals that the discordance rate between clinical
classification and the two-component classification is 1.4%
at most (2 errors in 148 variants). The sensitivities and
specificities of our two-component procedure compares
favorably with other diagnostic tools used in clinical
medicine.35 Based on these studies we surmise that the
two-component procedure may greatly improve the classi-
fication of variants in MMR genes, specifically in MSH6.
Furthermore, it is important to emphasize here that our
observation that many “pathogenic” variants produced in
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the screen retain significant Msh6 expression (Fig. 3a)
warrants great caution with the use of immunohistochem-
istry as a diagnostic criterion for LS.
With the increased deployment of exome sequencing for
cancer susceptibility it is expected that not only the total
number of identified variants, but also the relative incidence
of variants with reduced penetrance in MMR genes will
increase. The classification of intermediate-penetrance var-
iants represents the next challenge. We anticipate that this will
require the development of an extended classifier based on a
Bayesian integration of quantified clinical criteria (including
MSI and segregation) with our functional assay–based two-
component classification.4 This classification may be aided by
genetic screens as described here.
Finally, with the increased incidence of germline and
somatic variants in MMR genes and in other cancer-
predisposing genes, it is seminal to develop efficient and
validated diagnostic tools to enable the translation of
personalized genomics into personalized health care. The
approaches followed here provide a template for the
development of such tools.
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